Hansa Biopharma AB (publ) (HNSA) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and welcome to the HANSA Biopharma fourth quarter and full year 2025 financial results conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on a touch-tone phone. To withdraw your question, please press star then two. We ask that you limit yourself to one question, please. Please note that this event is being recorded. I would now like to turn the conference over to Hansa Biopharma CEO, Renee Aguiar-Lucander. Please go ahead. Thank you. Good afternoon and good morning. Welcome to the Hansa Biopharma Conference Calls Review Q4 and the results for the full year of 2025. I'm Renee Aguiar-Lucander. CEO of Hansa Biopharma, and joining me today is Evan Ballantyne, Chief Financial Officer, Richard Phillipson, Chief Medical Officer, and Maria Thornson, Chief Operating Officer and President, U.S. Please turn to slide two. Please allow me to draw your attention to the fact we'll be making forward-looking statements during this presentation, and you should therefore apply appropriate caution. Please turn to slide three and today's agenda. Move on to page four, please. In terms of key achievements in Q4, Q4 saw strong growth over the same quarter last year, with product revenue growth of almost 140% and total revenue growth of 135%. Total revenues for the year amounted to $222.3 million, or about $25 million, a growth of 46% compared to total revenues in 2024. In Q4, we successfully also closed an equity round of 671.5 million Swedish krona, or about 71 million US dollars, which will fund operations into 2027. As planned, we submitte...